UNMET NEED
•  The antibiotic resistance crisis, driven by the excessive and inappropriate use of antibiotics, is projected to result in 10 million deaths annually by 2050. Rapid and accurate diagnosis of multi-drug resistant (MDR) bacteria is essential to combat this growing global health threat.
•  There is a critical need for fast, reliable diagnostic tools capable of identifying bacterial pathogens directly at the point-of-care (POC), to support clinical decision-making, limit disease transmission, and reduce inappropriate antibiotic usage.

OUR SOLUTION
•  We have developed an innovative dual-channel antibody-based electrochemical biosensor for the rapid detection of pathogenic bacteria and profiling of antibiotic resistance.
•  The biosensor utilizes high-affinity monoclonal antibodies to detect specific bacterial markers with exceptional sensitivity and specificity.
•  The dual-channel format enables simultaneous or sequential detection of multiple targets, supporting comprehensive, multiplexed diagnostics in a single test.
•  The platform can be customized for different pathogens and resistance markers, making it suitable for diverse clinical and field applications.
•  Designed for point-of-care (POC) deployment, this system provides rapid, reliable results, facilitating informed treatment decisions and reducing misuse of antibiotics.

ADVANTAGE OVER EXISTING TECHNOLOGIES
•  Delivers rapid, cost-effective, and highly sensitive results directly at the POC—without the need for complex lab infrastructure or trained personnel.
•  The multiplexing capability allows detection of multiple pathogens and antibiotic resistance markers (e.g., beta-lactam resistance) in a single test, enabling more efficient diagnostics.
•  The dual-channel biosensor platform supports precision diagnostics and enhances antimicrobial stewardship by distinguishing between pathogenic and commensal strains.
•  The technology is scalable and versatile, allowing for expansion across various pathogens, resistance mechanisms, and diagnostic needs.

STATUS
•  Successfully developed and validated a novel dual-channel biosensor that detects enteropathogenic E. coli (EPEC) and exhibits excellent performance in identifying beta-lactam antibiotic resistance.
•  The biosensor has shown robust specificity, stability, and reproducibility in complex biological matrices including human feces.
•  Development of a second monoclonal antibody targeting a different pathogen is underway, enabling biosensor multiplexing for broader diagnostic capabilities.